Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 25 entries
Sorted by: Best Match Show Resources per page
Ezogabine: a new angle on potassium gates.

Epilepsy currents

Faught E.
PMID: 21686305
Epilepsy Curr. 2011 May;11(3):75-8. doi: 10.5698/1535-7511-11.3.75.

Ezogabine is a new drug for adjunctive therapy of partial-onset seizures with a novel mechanism of action. As a potassium-channel facilitator, it promotes membrane repolarization and thus opposes rapid repetitive discharges. Side effects are typical for antiepileptic drugs and...

Cite
Faught E. Ezogabine: a new angle on potassium gates. Epilepsy Curr. 2011;11(3):75-8doi: 10.5698/1535-7511-11.3.75.
Faught, E. (2011). Ezogabine: a new angle on potassium gates. Epilepsy currents, 11(3), 75-8. https://doi.org/10.5698/1535-7511-11.3.75
Faught, Edward. "Ezogabine: a new angle on potassium gates." Epilepsy currents vol. 11,3 (2011): 75-8. doi: https://doi.org/10.5698/1535-7511-11.3.75
Faught E. Ezogabine: a new angle on potassium gates. Epilepsy Curr. 2011 May;11(3):75-8. doi: 10.5698/1535-7511-11.3.75. PMID: 21686305; PMCID: PMC3117495.
Copy Download .nbib Format: NLM
Retigabine (ezogabine) as add-on therapy for partial-onset seizures: an update for clinicians.

Therapeutic advances in chronic disease

Harris JA, Murphy JA.
PMID: 23251762
Ther Adv Chronic Dis. 2011 Nov;2(6):371-6. doi: 10.1177/2040622311421542.

OBJECTIVE: The present study reviewed the pharmacology, pharmacokinetics, efficacy, and safety of retigabine (ezogabine), a potential agent for use as adjunctive treatment in refractory partial-onset seizures.METHODS: A MEDLINE search (1966-May 2011) was conducted using the key words retigabine, ezogabine,...

Cite
Harris JA, Murphy JA. Retigabine (ezogabine) as add-on therapy for partial-onset seizures: an update for clinicians. Ther Adv Chronic Dis. 2011;2(6):371-6doi: 10.1177/2040622311421542.
Harris, J. A., & Murphy, J. A. (2011). Retigabine (ezogabine) as add-on therapy for partial-onset seizures: an update for clinicians. Therapeutic advances in chronic disease, 2(6), 371-6. https://doi.org/10.1177/2040622311421542
Harris, Jacklyn A, and Murphy, Julie A. "Retigabine (ezogabine) as add-on therapy for partial-onset seizures: an update for clinicians." Therapeutic advances in chronic disease vol. 2,6 (2011): 371-6. doi: https://doi.org/10.1177/2040622311421542
Harris JA, Murphy JA. Retigabine (ezogabine) as add-on therapy for partial-onset seizures: an update for clinicians. Ther Adv Chronic Dis. 2011 Nov;2(6):371-6. doi: 10.1177/2040622311421542. PMID: 23251762; PMCID: PMC3513894.
Copy Download .nbib Format: NLM
Study of gender-related pharmacokinetics of ezogabine in Egyptian volunteers by a validated LC-MS/MS bioanalytical method.

Journal of advanced research

Elkady EF, Aboelwafa AA, Fouad MA.
PMID: 31956446
J Adv Res. 2019 Nov 22;22:99-104. doi: 10.1016/j.jare.2019.11.008. eCollection 2020 Mar.

Gender-based pharmacokinetics and/or pharmacodynamics differences can result in differences in treatment which can accordingly affect the drug safety and/or efficacy. A new validated bio-analytical LC-MS/MS method was developed for the estimation of ezogabine, a third-generation antiepileptic drug, in human...

Cite
Elkady EF, Aboelwafa AA, Fouad MA. Study of gender-related pharmacokinetics of ezogabine in Egyptian volunteers by a validated LC-MS/MS bioanalytical method. J Adv Res. 2019;22:99-104doi: 10.1016/j.jare.2019.11.008.
Elkady, E. F., Aboelwafa, A. A., & Fouad, M. A. (2020). Study of gender-related pharmacokinetics of ezogabine in Egyptian volunteers by a validated LC-MS/MS bioanalytical method. Journal of advanced research, 2299-104. https://doi.org/10.1016/j.jare.2019.11.008
Elkady, Ehab F, et al. "Study of gender-related pharmacokinetics of ezogabine in Egyptian volunteers by a validated LC-MS/MS bioanalytical method." Journal of advanced research vol. 22 (2020): 99-104. doi: https://doi.org/10.1016/j.jare.2019.11.008
Elkady EF, Aboelwafa AA, Fouad MA. Study of gender-related pharmacokinetics of ezogabine in Egyptian volunteers by a validated LC-MS/MS bioanalytical method. J Adv Res. 2019 Nov 22;22:99-104. doi: 10.1016/j.jare.2019.11.008. eCollection 2020 Mar. PMID: 31956446; PMCID: PMC6961218.
Copy Download .nbib Format: NLM
How to replace the lost keys? Strategies toward safer K.

Future medicinal chemistry

Bock C, Link A.
PMID: 30802153
Future Med Chem. 2019 Feb 25; doi: 10.4155/fmc-2018-0350. Epub 2019 Feb 25.

The highly structurally similar drugs flupirtine and retigabine have been regarded as safe and effective for many years but lately they turned out to exert intolerable side effects. While the twin molecules share the mode of action, both stabilize...

Cite
Bock C, Link A. How to replace the lost keys? Strategies toward safer K. Future Med Chem. 2019;doi: 10.4155/fmc-2018-0350.
Bock, C., & Link, A. (2019). How to replace the lost keys? Strategies toward safer K. Future medicinal chemistry, . https://doi.org/10.4155/fmc-2018-0350
Bock, Christian, and Link, Andreas. "How to replace the lost keys? Strategies toward safer K." Future medicinal chemistry vol. (2019). doi: https://doi.org/10.4155/fmc-2018-0350
Bock C, Link A. How to replace the lost keys? Strategies toward safer K. Future Med Chem. 2019 Feb 25; doi: 10.4155/fmc-2018-0350. Epub 2019 Feb 25. PMID: 30802153.
Copy Download .nbib Format: NLM
Retigabine-ezogabine: A new treatment option for bipolar disorder?.

Bipolar disorders

Mazza M, Marano G, Janiri L.
PMID: 30811779
Bipolar Disord. 2019 May;21(3):283-284. doi: 10.1111/bdi.12762. Epub 2019 Mar 13.

No abstract available.

Cite
Mazza M, Marano G, Janiri L. Retigabine-ezogabine: A new treatment option for bipolar disorder?. Bipolar Disord. 2019;21(3):283-284doi: 10.1111/bdi.12762.
Mazza, M., Marano, G., & Janiri, L. (2019). Retigabine-ezogabine: A new treatment option for bipolar disorder?. Bipolar disorders, 21(3), 283-284. https://doi.org/10.1111/bdi.12762
Mazza, Marianna, et al. "Retigabine-ezogabine: A new treatment option for bipolar disorder?." Bipolar disorders vol. 21,3 (2019): 283-284. doi: https://doi.org/10.1111/bdi.12762
Mazza M, Marano G, Janiri L. Retigabine-ezogabine: A new treatment option for bipolar disorder?. Bipolar Disord. 2019 May;21(3):283-284. doi: 10.1111/bdi.12762. Epub 2019 Mar 13. PMID: 30811779.
Copy Download .nbib Format: NLM
Clinical utility, safety, and tolerability of ezogabine (retigabine) in the treatment of epilepsy.

Drug, healthcare and patient safety

Ciliberto MA, Weisenberg JL, Wong M.
PMID: 22888276
Drug Healthc Patient Saf. 2012;4:81-6. doi: 10.2147/DHPS.S28814. Epub 2012 Jul 26.

One-third of patients with epilepsy continue to have seizures despite current treatments, indicating the need for better antiseizure medications with novel mechanisms of action. Ezogabine (retigabine) has recently been approved for adjunctive treatment of partial-onset seizures in adult patients...

Cite
Ciliberto MA, Weisenberg JL, Wong M. Clinical utility, safety, and tolerability of ezogabine (retigabine) in the treatment of epilepsy. Drug Healthc Patient Saf. 2012;4:81-6doi: 10.2147/DHPS.S28814.
Ciliberto, M. A., Weisenberg, J. L., & Wong, M. (2012). Clinical utility, safety, and tolerability of ezogabine (retigabine) in the treatment of epilepsy. Drug, healthcare and patient safety, 481-6. https://doi.org/10.2147/DHPS.S28814
Ciliberto, Michael A, et al. "Clinical utility, safety, and tolerability of ezogabine (retigabine) in the treatment of epilepsy." Drug, healthcare and patient safety vol. 4 (2012): 81-6. doi: https://doi.org/10.2147/DHPS.S28814
Ciliberto MA, Weisenberg JL, Wong M. Clinical utility, safety, and tolerability of ezogabine (retigabine) in the treatment of epilepsy. Drug Healthc Patient Saf. 2012;4:81-6. doi: 10.2147/DHPS.S28814. Epub 2012 Jul 26. PMID: 22888276; PMCID: PMC3413039.
Copy Download .nbib Format: NLM
Age dependent effects of Retigabine on absence seizure in WAG/Rij rats; an experimental study.

Clinical and experimental pharmacology & physiology

Karadenizli S, Şahin D, Ateş N.
PMID: 34133772
Clin Exp Pharmacol Physiol. 2021 Sep;48(9):1251-1260. doi: 10.1111/1440-1681.13537. Epub 2021 Jul 04.

Retigabine (RTG, Ezogabine, DC23129) is the first neuronal potassium channel opener in the treatment of epilepsy and exerts its effects through the activation of neuronal KCNQ2/3 potassium channels; in higher doses, it acts also on sodium and voltage-gated calcium...

Cite
Karadenizli S, Şahin D, Ateş N. Age dependent effects of Retigabine on absence seizure in WAG/Rij rats; an experimental study. Clin Exp Pharmacol Physiol. 2021;48(9):1251-1260doi: 10.1111/1440-1681.13537.
Karadenizli, S., Şahin, D., & Ateş, N. (2021). Age dependent effects of Retigabine on absence seizure in WAG/Rij rats; an experimental study. Clinical and experimental pharmacology & physiology, 48(9), 1251-1260. https://doi.org/10.1111/1440-1681.13537
Karadenizli, Sabriye, et al. "Age dependent effects of Retigabine on absence seizure in WAG/Rij rats; an experimental study." Clinical and experimental pharmacology & physiology vol. 48,9 (2021): 1251-1260. doi: https://doi.org/10.1111/1440-1681.13537
Karadenizli S, Şahin D, Ateş N. Age dependent effects of Retigabine on absence seizure in WAG/Rij rats; an experimental study. Clin Exp Pharmacol Physiol. 2021 Sep;48(9):1251-1260. doi: 10.1111/1440-1681.13537. Epub 2021 Jul 04. PMID: 34133772.
Copy Download .nbib Format: NLM
Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.

JAMA neurology

Wainger BJ, Macklin EA, Vucic S, McIlduff CE, Paganoni S, Maragakis NJ, Bedlack R, Goyal NA, Rutkove SB, Lange DJ, Rivner MH, Goutman SA, Ladha SS, Mauricio EA, Baloh RH, Simmons Z, Pothier L, Kassis SB, La T, Hall M, Evora A, Klements D, Hurtado A, Pereira JD, Koh J, Celnik PA, Chaudhry V, Gable K, Juel VC, Phielipp N, Marei A, Rosenquist P, Meehan S, Oskarsson B, Lewis RA, Kaur D, Kiskinis E, Woolf CJ, Eggan K, Weiss MD, Berry JD, David WS, Davila-Perez P, Camprodon JA, Pascual-Leone A, Kiernan MC, Shefner JM, Atassi N, Cudkowicz ME.
PMID: 33226425
JAMA Neurol. 2021 Feb 01;78(2):186-196. doi: 10.1001/jamaneurol.2020.4300.

IMPORTANCE: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease of the motor nervous system. Clinical studies have demonstrated cortical and spinal motor neuron hyperexcitability using transcranial magnetic stimulation and threshold tracking nerve conduction studies, respectively, although metrics of...

Cite
Wainger BJ, Macklin EA, Vucic S, et al. Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Neurol. 2021;78(2):186-196doi: 10.1001/jamaneurol.2020.4300.
Wainger, B. J., Macklin, E. A., Vucic, S., McIlduff, C. E., Paganoni, S., Maragakis, N. J., Bedlack, R., Goyal, N. A., Rutkove, S. B., Lange, D. J., Rivner, M. H., Goutman, S. A., Ladha, S. S., Mauricio, E. A., Baloh, R. H., Simmons, Z., Pothier, L., Kassis, S. B., La, T., Hall, M., Evora, A., Klements, D., Hurtado, A., Pereira, J. D., Koh, J., Celnik, P. A., Chaudhry, V., Gable, K., Juel, V. C., Phielipp, N., Marei, A., Rosenquist, P., Meehan, S., Oskarsson, B., Lewis, R. A., Kaur, D., Kiskinis, E., Woolf, C. J., Eggan, K., Weiss, M. D., Berry, J. D., David, W. S., Davila-Perez, P., Camprodon, J. A., Pascual-Leone, A., Kiernan, M. C., Shefner, J. M., Atassi, N., & Cudkowicz, M. E. (2021). Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA neurology, 78(2), 186-196. https://doi.org/10.1001/jamaneurol.2020.4300
Wainger, Brian J, et al. "Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial." JAMA neurology vol. 78,2 (2021): 186-196. doi: https://doi.org/10.1001/jamaneurol.2020.4300
Wainger BJ, Macklin EA, Vucic S, McIlduff CE, Paganoni S, Maragakis NJ, Bedlack R, Goyal NA, Rutkove SB, Lange DJ, Rivner MH, Goutman SA, Ladha SS, Mauricio EA, Baloh RH, Simmons Z, Pothier L, Kassis SB, La T, Hall M, Evora A, Klements D, Hurtado A, Pereira JD, Koh J, Celnik PA, Chaudhry V, Gable K, Juel VC, Phielipp N, Marei A, Rosenquist P, Meehan S, Oskarsson B, Lewis RA, Kaur D, Kiskinis E, Woolf CJ, Eggan K, Weiss MD, Berry JD, David WS, Davila-Perez P, Camprodon JA, Pascual-Leone A, Kiernan MC, Shefner JM, Atassi N, Cudkowicz ME. Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Neurol. 2021 Feb 01;78(2):186-196. doi: 10.1001/jamaneurol.2020.4300. PMID: 33226425; PMCID: PMC7684515.
Copy Download .nbib Format: NLM
KCNQ2 encephalopathy: Features, mutational hot spots, and ezogabine treatment of 11 patients.

Neurology. Genetics

Millichap JJ, Park KL, Tsuchida T, Ben-Zeev B, Carmant L, Flamini R, Joshi N, Levisohn PM, Marsh E, Nangia S, Narayanan V, Ortiz-Gonzalez XR, Patterson MC, Pearl PL, Porter B, Ramsey K, McGinnis EL, Taglialatela M, Tracy M, Tran B, Venkatesan C, Weckhuysen S, Cooper EC.
PMID: 27602407
Neurol Genet. 2016 Aug 22;2(5):e96. doi: 10.1212/NXG.0000000000000096. eCollection 2016 Oct.

OBJECTIVE: To advance the understanding of KCNQ2 encephalopathy genotype-phenotype relationships and to begin to assess the potential of selective KCNQ channel openers as targeted treatments.METHODS: We retrospectively studied 23 patients with KCNQ2 encephalopathy, including 11 treated with ezogabine (EZO)....

Cite
Millichap JJ, Park KL, Tsuchida T, et al. KCNQ2 encephalopathy: Features, mutational hot spots, and ezogabine treatment of 11 patients. Neurol Genet. 2016;2(5):e96doi: 10.1212/NXG.0000000000000096.
Millichap, J. J., Park, K. L., Tsuchida, T., Ben-Zeev, B., Carmant, L., Flamini, R., Joshi, N., Levisohn, P. M., Marsh, E., Nangia, S., Narayanan, V., Ortiz-Gonzalez, X. R., Patterson, M. C., Pearl, P. L., Porter, B., Ramsey, K., McGinnis, E. L., Taglialatela, M., Tracy, M., Tran, B., Venkatesan, C., Weckhuysen, S., & Cooper, E. C. (2016). KCNQ2 encephalopathy: Features, mutational hot spots, and ezogabine treatment of 11 patients. Neurology. Genetics, 2(5), e96. https://doi.org/10.1212/NXG.0000000000000096
Millichap, John J, et al. "KCNQ2 encephalopathy: Features, mutational hot spots, and ezogabine treatment of 11 patients." Neurology. Genetics vol. 2,5 (2016): e96. doi: https://doi.org/10.1212/NXG.0000000000000096
Millichap JJ, Park KL, Tsuchida T, Ben-Zeev B, Carmant L, Flamini R, Joshi N, Levisohn PM, Marsh E, Nangia S, Narayanan V, Ortiz-Gonzalez XR, Patterson MC, Pearl PL, Porter B, Ramsey K, McGinnis EL, Taglialatela M, Tracy M, Tran B, Venkatesan C, Weckhuysen S, Cooper EC. KCNQ2 encephalopathy: Features, mutational hot spots, and ezogabine treatment of 11 patients. Neurol Genet. 2016 Aug 22;2(5):e96. doi: 10.1212/NXG.0000000000000096. eCollection 2016 Oct. PMID: 27602407; PMCID: PMC4995058.
Copy Download .nbib Format: NLM
New antiepileptic medication linked to blue discoloration of the skin and eyes.

Therapeutic advances in drug safety

Clark S, Antell A, Kaufman K.
PMID: 25642319
Ther Adv Drug Saf. 2015 Feb;6(1):15-9. doi: 10.1177/2042098614560736.

Ezogabine is an antiepileptic medication approved in June 2011 by the US Food and Drug Administration (FDA) as an adjunctive treatment for partial seizures. Minimal drug interactions and a novel mechanism of action made ezogabine an appealing new treatment...

Cite
Clark S, Antell A, Kaufman K. New antiepileptic medication linked to blue discoloration of the skin and eyes. Ther Adv Drug Saf. 2015;6(1):15-9doi: 10.1177/2042098614560736.
Clark, S., Antell, A., & Kaufman, K. (2015). New antiepileptic medication linked to blue discoloration of the skin and eyes. Therapeutic advances in drug safety, 6(1), 15-9. https://doi.org/10.1177/2042098614560736
Clark, Sarah, et al. "New antiepileptic medication linked to blue discoloration of the skin and eyes." Therapeutic advances in drug safety vol. 6,1 (2015): 15-9. doi: https://doi.org/10.1177/2042098614560736
Clark S, Antell A, Kaufman K. New antiepileptic medication linked to blue discoloration of the skin and eyes. Ther Adv Drug Saf. 2015 Feb;6(1):15-9. doi: 10.1177/2042098614560736. PMID: 25642319; PMCID: PMC4308410.
Copy Download .nbib Format: NLM
Investigation of the impact of urine handling procedures on interpretation of urinalysis findings and product safety in subjects treated with ezogabine.

Therapeutics and clinical risk management

Brickel N, Derossett S, Buraglio M, Evans C, Jones S.
PMID: 23671389
Ther Clin Risk Manag. 2013;9:207-13. doi: 10.2147/TCRM.S42536. Epub 2013 May 07.

BACKGROUND: Ezogabine (also known by the international nonproprietary name of retigabine) is an antiepileptic drug codeveloped and comarketed by Valeant Pharmaceuticals North America and GlaxoSmithKline, which reduces neuronal excitability by enhancing the activity of potassium channels and has the...

Cite
Brickel N, Derossett S, Buraglio M, et al. Investigation of the impact of urine handling procedures on interpretation of urinalysis findings and product safety in subjects treated with ezogabine. Ther Clin Risk Manag. 2013;9:207-13doi: 10.2147/TCRM.S42536.
Brickel, N., Derossett, S., Buraglio, M., Evans, C., & Jones, S. (2013). Investigation of the impact of urine handling procedures on interpretation of urinalysis findings and product safety in subjects treated with ezogabine. Therapeutics and clinical risk management, 9207-13. https://doi.org/10.2147/TCRM.S42536
Brickel, Neil, et al. "Investigation of the impact of urine handling procedures on interpretation of urinalysis findings and product safety in subjects treated with ezogabine." Therapeutics and clinical risk management vol. 9 (2013): 207-13. doi: https://doi.org/10.2147/TCRM.S42536
Brickel N, Derossett S, Buraglio M, Evans C, Jones S. Investigation of the impact of urine handling procedures on interpretation of urinalysis findings and product safety in subjects treated with ezogabine. Ther Clin Risk Manag. 2013;9:207-13. doi: 10.2147/TCRM.S42536. Epub 2013 May 07. PMID: 23671389; PMCID: PMC3650885.
Copy Download .nbib Format: NLM
Physician and Pharmacist Understanding of the Risk of Urinary Retention with Retigabine (Ezogabine): A REMS Assessment Survey.

Drugs - real world outcomes

Ishihara L, Beck M, Travis S, Akintayo O, Brickel N.
PMID: 26690543
Drugs Real World Outcomes. 2015;2(4):335-344. doi: 10.1007/s40801-015-0042-5. Epub 2015 Oct 07.

BACKGROUND: The Risk Evaluation and Mitigation Strategy (REMS) for retigabine/ezogabine (RTG/EZG) required an evaluation of the effectiveness of the communication plan to communicate about the risks with use of RTG/EZG.OBJECTIVE: GlaxoSmithKline conducted a survey to assess understanding of the...

Cite
Ishihara L, Beck M, Travis S, et al. Physician and Pharmacist Understanding of the Risk of Urinary Retention with Retigabine (Ezogabine): A REMS Assessment Survey. Drugs Real World Outcomes. 2015;2(4):335-344doi: 10.1007/s40801-015-0042-5.
Ishihara, L., Beck, M., Travis, S., Akintayo, O., & Brickel, N. (2015). Physician and Pharmacist Understanding of the Risk of Urinary Retention with Retigabine (Ezogabine): A REMS Assessment Survey. Drugs - real world outcomes, 2(4), 335-344. https://doi.org/10.1007/s40801-015-0042-5
Ishihara, Lianna, et al. "Physician and Pharmacist Understanding of the Risk of Urinary Retention with Retigabine (Ezogabine): A REMS Assessment Survey." Drugs - real world outcomes vol. 2,4 (2015): 335-344. doi: https://doi.org/10.1007/s40801-015-0042-5
Ishihara L, Beck M, Travis S, Akintayo O, Brickel N. Physician and Pharmacist Understanding of the Risk of Urinary Retention with Retigabine (Ezogabine): A REMS Assessment Survey. Drugs Real World Outcomes. 2015;2(4):335-344. doi: 10.1007/s40801-015-0042-5. Epub 2015 Oct 07. PMID: 26690543; PMCID: PMC4674522.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 25 entries